Introduction
The incidence of cutaneous melanoma in the head and neck region has increased in recent years, along with an overall increase in the incidence of cutaneous melanoma world-wide. The key to survival is early detection of this malignancy and indeed melanoma is currently diagnosed in an earlier stage with thinner melanoma. 1 Early detection and treatment of micrometastatic disease might further improve recurrence-free and overall survival. Primary cutaneous melanomas in the head and neck region are considered to be more aggressive than melanomas on the arms and legs. 2 Therefore, debate continues about the best management for clinically negative cervical lymph nodes. Prospective studies, performed in the past did not proof any benefi t of elective lymphatic dissection for these patients. [3] [4] [5] A combination of high relapse rates and the persisting lack of eff ective treatment for recurrent disease has focused attention on optimizing initial management as a means of improving the overall outcome. The value and reliability of sentinel lymph node biopsy as a staging procedure in melanoma have been well-described in the literature since it was fi rst reported in 1990, but fi nal results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) are still pending. 6, 7 Sentinel lymph node biopsy can identify indeed patients who may theoretically benefi t from complete lymph node dissection. Melanomas located on the head and neck have an extremely unpredictable drainage pattern. 8, 9 Sentinel lymph node biopsy in the head and neck region presents unique challenges in terms of anatomy and surgical technique. The value, safety, reliability, recurrence-free and overall survival rates of sentinel lymph node biopsy in patients with cutaneous melanoma in the head and neck region were evaluated and discussed with respect to the current literature.
Materials and methods

Patients
From May 1995 to 2005, 36 patients (15 females (42%) and 21 males (58%)), median age 58 years (range, 25-79 years) with a cutaneous melanoma ≥1.0 mm Breslow thickness in the head and neck region were enrolled in a prospective registration study at the Division of Surgical Oncology of the UMCG. Informed consent was obtained from all patients. The primary melanomas were diagnosed by excisional biopsy. None of these patients had undergone excision of the primary tumour with margins of >1.5 cm. Patients with palpable regional lymph nodes and/or clinical evidence of distant metastases, pregnant women and children and adolescents (<18 years) were excluded from this study.
Lymphoscintigraphy
A 2-day protocol on an inpatient basis was used. Lymphoscintigraphy was performed on the day preceding the operation. A single dose of unfi ltered 40-60 MBq 99m Tc-nanocolloid (Nanocoll®; Amersham Cygne, Eindhoven, the Netherlands) with a particle size of <80 nm in 0.2 ml of saline was injected intradermally around the primary tumour site at two to Chapter VII 98 99 four locations. Injection sites were covered with lead shielding. Dynamic imaging in the supine position with a low energy high resolution collimator to visualize lymph fl ow was commenced immediately after tracer administration and continued for 20 minutes at a frame rate of 30 sec/image. Subsequently, static supine and lateral views were obtained. A radioactive fl ood source was used to outline the body contour. Another set of static images was taken two hours later. All possible lymph drainage regions were imaged. The position of the sentinel lymph node(s) was marked on the skin with indelible ink. The images were discussed by an interdisciplinary team comprising the nuclear medicine physician and the surgical oncologist prior to the operation.
Surgery
After the induction of general anesthesia, but 15-20 minutes before surgery, an injection of 0.3-1.0 ml Patent Blue V (Bleu Patenté V, Laboratoire Guerbet, Aulnaysous-Bois, France) was administered intradermally around the melanoma scar. All nodal basins identifi ed by lymphoscintigraphy were explored surgically through limited incisions. Surgical dissection was guided by a hand-held gamma detection probe (Neoprobe®1000 and 1500, Johnson & Johnson Medical BV) and by looking for blue-stained aff erent lymphatic vessels that led to blue-stained sentinel lymph nodes. Once the sentinel lymph nodes had been excised the probe was used to search the resection bed to ensure that there were no residual areas of high radioactivity. If necessary, additional hot nodes were removed until the ratio of the hottest ex vivo sentinel lymph node to the residual basin was >10:1. 10 After sentinel lymph node biopsy, wide local excision of the primary melanoma scar was performed with 1 or 2 cm margin depending on the tumour thickness (Breslow) and the anatomical location of the melanoma. If pathological examination was positive for tumour cells on HE or immunohistochemical (IHC) staining, cervical or posterior lymph node dissection was performed with the standard surgical procedure. If sentinel lymph nodes were negative for tumour cells on pathological examination, the lymph node basins were monitored clinically during follow-up.
Pathology
After marking the hottest part of the sentinel lymph node with a stitch, each harvested sentinel lymph node was sent for pathological examination. Owing to low sensitivity (38%) of frozen section analysis with HE in the fi rst 11 patients, we subsequently delayed sentinel lymph node evaluation in order to perform permanent sectioning. The sentinel lymph nodes were fi xed in 10% neutral buff ered formalin and blocked in paraffi n. Serial 4 μm thick sections of all paraffi n-embedded material were evaluated with routine HE and IHC staining for S100 protein and melanoma-associated antigen HMB45. This procedure was repeated at levels of 500 μm until all the tissue was sectioned (average: 9 levels). Two paraffi n-embedded cross-sections of each lymph node were stained with HE without any additional IHC.
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Follow-up Patients were seen for physical examination every 3, 4, 6 and 12 months in the 1 st , 2 nd , 3 rd -5 th and 5 th -10 th years, respectively. A chest X-ray was taken once a year. In patients who developed tumour recurrence in the same nodal basin, recurrence patterns were analyzed. All previously identifi ed tumour-negative sentinel lymph nodes were re-evaluated on original slides and IHC-stained additional deeper sections of the sentinel lymph nodes. Duration of follow-up was calculated in months from the date of sentinel lymph node biopsy to the date of last follow-up or death. None of the patients were lost to follow-up. Median follow-up was 54 (range, 10-114) months.
Statistical analysis
Recurrence-free and overall survival curves were constructed for sentinel lymph nodepositive and sentinel lymph node-negative patients using the Kaplan-Meier method and compared using the log-rank procedure. Signifi cance was defi ned as P<0.05. Results are presented as median (range) and as percentages when appropriate.
Results
Fifteen females (42%) and 21 males (58%) with a median age of 58 (range, 25-79) years with a cutaneous melanoma ≥1.0 mm Breslow thickness (median 2.5 mm; range, 1.0-8.1) were included (Table 1) . At least one sentinel lymph node was identifi ed in 33 (92%) out of the 36 patients. Wide local resection with 1-2 cm margin had to be performed before sentinel lymph node biopsy in 10 patients (28%), to reduce the high background counts that interfered with sentinel lymph node localization by the gamma detection probe. A total of 97 sentinel lymph nodes were excised (median 2.9 nodes per patient; range, 1-7). These 97 sentinel lymph nodes were removed from a total of 48 nodal basins (median 1.5 basin per patient; range, 1-3). In 23 patients (70%) the blue tracer was seen together with the radioactive tracer intraoperatively. In 10 patients (30%) the sentinel lymph nodes were identifi ed by the radioactive tracer alone. In two patients, sentinel lymph nodes were identifi ed in an unexpected node fi eld, that is, the supraclavicular basin. In one of them with a primary lesion on the earlobe, dynamic lymphoscintigraphy showed direct drainage to both the parotid region and the supraclavicular region. In the other patient, direct drainage was seen from the preauricular melanoma scar site to the subdigastric and supraclavicular regions. In both patients, histopathology of the sentinel lymph nodes in the unexpected and expected basins was tumour-negative. In 17 patients (47%), lymphoscintigraphy showed a sentinel lymph node in the parotid region. All sentinel lymph nodes could be identifi ed in this region (success rate 100%). In 12 patients (71%), the parotid sentinel lymph nodes were tumour-free. In fi ve patients (29%) the parotid sentinel lymph nodes were tumour-positive. These patients underwent subtotal parotidectomy with modifi ed neck dissection. No additional tumour-positive lymph nodes were found on histopathological examination. After exploration of the parotid gland or after re-operation that comprised subtotal parotidectomy no complications occurred. In total, a tumour-positive sentinel lymph node was diagnosed in seven patients (tumour-positive sentinel lymph node-rate 21%). So far, 12 patients (33%) have developed recurrence of the disease. The distribution of the fi rst site of the metastases was as follows: 4 (11%) with in-transit recurrence; 2 (6%) with recurrence in the regional lymph node basin and 6 (17%) with a distant recurrence. The distribution of the fi rst site of the metastases according to tumour status of the sentinel lymph node is shown in Table 2 . The sentinel lymph node biopsy result was falsenegative in one of seven positive sentinel lymph node biopsy results (false-negative rate 13%). Recurrence-free and overall survival rates were not signifi cantly associated with the results of the sentinel lymph node biopsy. The fi ve-year recurrence-free survival in sentinel lymph node-tumour-negative patients and sentinel lymph node-tumour-positive patients was 65% and 50% respectively (P<0.6133). The overall survival at 5 years was 55% and 66% respectively (P<0.5951) (Figures 1 and 2) . The overall morbidity related to this procedure was minimal. No anaphylactic reactions occurred following the injection of radioactive tracer or Patent Blue V. All the patients had normal postoperative cranial nerve function, including the facial nerve. 
SLN-=sentinel lymph node tumour-negative,
Discussion
Sentinel lymph node biopsy in head and neck melanoma is a challenge for the surgeon. In this series sentinel lymph node biopsy succeeded in 33 out of the 36 patients (success rate 92%). This is in contrast to our series of 266 non-head and neck melanoma patients in which we could identify all sentinel lymph nodes (success rate 100%). 11 Various features may have contributed to the failures: (1) primary tumour site overlying the draining basin(s), (2) learning curve of the surgeon, (3) high radioactivity level (40-60 MBq), (4) lymphoscintigraphy collimator problems, artefacts, (5) volume of tracer too large, (6) spillover into second echelon nodes and (7) incorrect injection technique, that is, if injection is not intradermal, the lymphatic drainage may not be adequately demonstrated.
The success rate of sentinel lymph node biopsy in the parotid region was 100%. After sentinel lymph node biopsy in the parotid region, no complications were observed. Our experience supports the fi ndings of others that sentinel lymph node biopsy of intraparotid nodes can be performed safely by experienced surgical oncologists specialized in surgical oncology procedures in the head and neck area without formal parotidectomy. 12, 13 The procedure was performed with equivalent safety in the neck and parotid nodal basins. In our opinion, when it has been decided to do a sentinel lymph node biopsy, surgical oncologists should not be reluctant to perform subtotal parotidectomy and/or posterolateral neck dissection if the sentinel lymph node biopsy result is tumourpositive. Is our false-negative rate of 13% high? Table 3 illustrates the great variation in the falsenegative rates for sentinel lymph node biopsy procedures in head and neck melanoma as published in the literature. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Does sentinel lymph node biopsy in cutaneous head and neck melanoma alter disease outcome? In determining the rate of false-negative results, a mistake that is sometimes made is to calculate the rate over the entire group of patients, both those who are tumour-positive and those who are tumour-negative. The outcome is too fl attering with this approach. It is not possible to miss metastasis in a patient who has no metastasis. The false-negative rate should be calculated over the entire group of tumour-positive patients, as follows:
number of false-negative procedures False-negative rate = ___________________________________________ x 100% number of false-negative + true-positive procedures
The false-negative rates in Table 3 are adjusted accordingly. 32 The number of patients with a positive sentinel lymph node in our study was small, which might have led to a high false-negative rate on the basis of one false-negative result. Reporting the false-negative rate for this procedure is problematic, because it is diffi cult to make a reliable assessment of the status of the remainder of the nodal basin by using non-surgical means. The most accurate approach would be to perform lymph node dissection immediately after sentinel lymph node biopsy, so that the status of the entire 'at risk' nodal basin can be compared to that of the sentinel lymph node(s). An ideal solution would be to examine sentinel lymph nodes and non-sentinel lymph nodes using immunohistochemical methods and serial sectioning in equal detail to enable a truly valid evaluation of the technique, but this is obviously impractical. We used the current, generally more acceptable method to determine false-negative rates: documentation of the rate of nodal failure over time within sentinel lymph node-negative basins. The performance of sentinel lymph node biopsy may in itself alter the pattern of subse-Does sentinel lymph node biopsy in cutaneous head and neck melanoma alter disease outcome? SLN-SLN+ quent recurrence of melanoma, thus increasing the incidence of in-transit recurrence. 33, 34 In-transit recurrence is defi ned as that occurring between the primary excision site and the regional node basin, but excluding local recurrences within 3 cm of the primary tumour site. In this small series we found two cases in sentinel lymph node-positive (2/7=29%) and two cases in sentinel lymph node-negative (2/26=8%) patients. Also other series are now publishing high incidence rates in sentinel lymph node-positive patients (Table 4 ). However, our concern is not shared by others like Coit 51 , who stated that the overall incidence of in-transit recurrence after sentinel lymph node biopsy is low and is most likely infl uenced much more by patient, tumour, and lymph node variables than by any treatment variable.
Conclusions
In the head and neck region, the multiplicity of lymph nodes, their widespread distribution, small size and their proximity to vulnerable structures make the sentinel lymph node biopsy procedure technically challenging. This study addressed the value, safety and reliability of sentinel lymph node biopsy to accurately detect occult regional metastases in patients with cutaneous melanoma in the head and neck region. During a median follow-up of 4½ years, one patient developed an isolated regional recurrence following a tumour-negative sentinel lymph node biopsy. A sensitivity rate of 87% with minimal morbidity indicates that sentinel lymph node biopsy is a reliable procedure for regional staging of patients with cutaneous melanoma in the head and neck region.
Recurrence-free and overall survival were not signifi cantly associated with the results of sentinel lymph node biopsy, but the number of patients in this study was too small to draw any defi nitive conclusions. The main question which is still unanswered is whether sentinel lymph node biopsy will improve recurrence-free and overall survival. Results of MSLT-I are pending. 7 Although no consensus has been reached among investigators as to whether sentinel lymph node biopsy followed by early regional node dissection improves regional tumour control (and patient survival), lymphatic mapping defi nitely provides prognostic information. 52 If this is also true for head and neck melanoma is questionable and is not supported by this small study.
